Stock Quote
Data Provided by Refinitiv. Minimum 15 minutes delayed.
We are a clinical-stage biotechnology company developing therapeutics that are designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Our initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2, which play key roles in regulating fibrosis. We believe our product candidates are distinct from the current generation of antifibrotic agents and have the potential to significantly improve patients’ clinical outcomes and enhance their quality of life.
Our lead product candidate is an inhaled galectin-3 modulator, GB0139, currently in a Phase 2b study for the treatment of idiopathic pulmonary fibrosis. Our pipeline also includes an orally active galectin-3 inhibitor, GB1211, that is expected to be part of (i) a phase 2 trial for the potential treatment of NSCLC in combination with an anti-PD1/-L1 product and (ii) a phase 1b/2a trial in liver cirrhosis, as well as an orally active LOXL2 inhibitor, GB2064, that is part of an ongoing phase 2 trial for the potential treatment of myelofibrosis.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Management will be available for 1x1 meetings throughout the day. There is no presentation/webcast associated with this event.
Galecto will host a key opinion leader event to discuss the current treatment landscape and unmet clinical need for myelofibrosis, as well as the potential for GB2064, Galecto’s LOXL2 inhibitor that is expected to enter a phase 2 trial in the current quarter.